8-chloro-1,4,5,6-tetrahydrobenzo[f]-quinolin-3(2H)-one | 113075-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-chloro-1,4,5,6-tetrahydrobenzo[f]-quinolin-3(2H)-one
• 英文别名: 8-chloro-1,4,5,6-tetrahydrobenzo-quinolin-3-one；8-chloro-1,2,3,4,5,6-hexahydrobenzo[f]quinolin-3-one；8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one；8-chloro-2,4,5,6-tetrahydro-1H-benzo[f]quinolin-3-one
• CAS: 113075-47-1
• 化学式: C₁₃H₁₂ClNO
• 分子量: 233.697
• InChiKey: HPNWYKAOJZXFSL-UHFFFAOYSA-N

物化性质

• 沸点：
  466.6±45.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-chloro-1,4,5,6-tetrahydrobenzo[f]-quinolin-3(2H)-one 在 三乙基硅烷 、 sodium hydride 、 三氟乙酸 作用下， 生成 8-chloro-4-methyl-1,2,3,4,4a,5,6,10b-cis-octahydrobenzo-quinolin-3-one
  参考文献：
  名称：

  人类I型类固醇5-α-还原酶的非类固醇抑制剂。

  摘要：

  DOI：

  10.1021/jm00055a014
• 作为产物：
  描述：

  对氯苯乙酸 以35%的产率得到8-chloro-1,4,5,6-tetrahydrobenzo[f]-quinolin-3(2H)-one
  参考文献：
  名称：

  Hexahydrobenzo[f]quinolinones

  摘要：

  该发明涉及1,2,3,4,5,6-六氢苯并[f]喹啉-3-酮，含有这些化合物的药物配方，以及它们作为类固醇5α-还原酶抑制剂的用途。

  公开号：

  US05250539A1

文献信息

• Hydrocinnamic acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04883815A1

  公开（公告）日：1989-11-28

  Hydrocinnamic acid derivatives of the formula ##STR1## wherein one or two of the symbols R.sup.1 to R.sup.4 are halogen or methoxy and the others are hydrogen; R.sup.5 is hydrogen or phenyl; R.sup.6 is a residue of the formula ##STR2## R.sup.7 is (C.sub.1 -C.sub.4)-alkyl, (C.sub.2 -C.sub.5)-alkanoylamino-(C.sub.2 -C.sub.5)-alkyl, amino or (C.sub.1 -C.sub.4)-alkoxyphenyl; R.sup.8 and R.sup.9 each, independently, are hydrogen or (C.sub.1 -C.sub.4)-alkyl; R.sup.10 is hydrogen and R.sup.11 is hydroxy or R.sup.10 and R.sup.11 taken together are oxo; R.sup.12 is hydrogen, (C.sub.1 -C.sub.10)-alkyl, pyridylmethyl or carbamoylmethyl; R.sup.13 is hydrogen, (C.sub.1 -C.sub.4)-alkyl and R.sup.14 is hydrogen, (C.sub.1 -C.sub.4)-alkyl, pyridyl, phenyl-(C.sub.1 -C.sub.4)-alkyl, carboxy-(C.sub.1 -C.sub.4)-alkyl, carbamoyl-(C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy carbonyl-(C.sub.1 -C.sub.4)-alkyl, di-(C.sub.1 -C.sub.4)-alkoxy carbonyl-C.sub.2 -C.sub.5)-alky, piperidino-C.sub.2 -C.sub.4)-alkyl or halopyridinecarboxamido-(C.sub.2 -C.sub.4)-alkyl or R.sup.13 and R.sup.14 taken together with the nitrogen atom are 4-(C.sub.1 -C.sub.4)-alkyl-piperazin-1-yl, as well as pharmaceutically acceptable salts of basic compounds of formula I with acids or of acidic compounds of formula I with bases are described. The compounds of formula I and their pharmaceutically acceptable salts are suitable for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions.

  公式为##STR1##的羟肉桂酸衍生物，其中符号R.sup.1至R.sup.4中的一个或两个是卤素或甲氧基，其余为氢；R.sup.5为氢或苯基；R.sup.6为##STR2##的残基；R.sup.7为(C.sub.1 -C.sub.4)-烷基，(C.sub.2 -C.sub.5)-辛酰胺基-(C.sub.2 -C.sub.5)-烷基，氨基或(C.sub.1 -C.sub.4)-烷氧基苯基；R.sup.8和R.sup.9各自独立地为氢或(C.sub.1 -C.sub.4)-烷基；R.sup.10为氢，R.sup.11为羟基或R.sup.10和R.sup.11一起为氧代；R.sup.12为氢，(C.sub.1 -C.sub.10)-烷基，吡啶甲基或氨甲酰甲基；R.sup.13为氢，(C.sub.1 -C.sub.4)-烷基，R.sup.14为氢，(C.sub.1 -C.sub.4)-烷基，吡啶，苯基-(C.sub.1 -C.sub.4)-烷基，羧基-(C.sub.1 -C.sub.4)-烷基，氨甲酰-(C.sub.1 -C.sub.4)-烷基，(C.sub.1 -C.sub.4)-烷氧基羰基-(C.sub.1 -C.sub.4)-烷基，二-(C.sub.1 -C.sub.4)-烷氧基羰基-C.sub.2 -C.sub.5)-烷基，哌哆啶-C.sub.2 -C.sub.4)-烷基或卤代吡啶基羧酰胺基-(C.sub.2 -C.sub.4)-烷基或R.sup.13和R.sup.14与氮原子一起为4-(C.sub.1 -C.sub.4)-烷基-哌嗪-1-基，以及公式I的碱性化合物的药学上可接受的盐与酸或公式I的酸性化合物的药学上可接受的盐与碱描述。公式I的化合物及其药学上可接受的盐适用于控制或预防脑部供血不足或改善认知功能。
• Benzazecine derivatives for cognitive and memory functions
  申请人：Hoffmann-La Roche Inc.

  公开号：US04732979A1

  公开（公告）日：1988-03-22

  Benzazecinediones of the formula ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen or chlorine, R.sup.3 is hydrogen, fluorine, chlorine, bromine or methoxy, R.sup.4 is hydrogen, chlorine or methoxy and R.sup.5 is hydrogen, acetyl, propionyl, benzoyl, chlorobenzoyl, methoxybenzoyl or phenylacetyl, with the proviso that 2 or 3 of the groups R.sup.1 to R.sup.4 are hydrogen. as well as many of the corresponding benzo[f]quinolines from which these benzazecinediones can be prepared by oxidation are suitable for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions in mammals. They can be produced according to various processes and can be prepared into pharmaceutical compositions.

  苯并环丙二酮类化合物的化学式为##STR1##其中R.sup.1和R.sup.2独立地为氢或氯，R.sup.3为氢、氟、氯、溴或甲氧基，R.sup.4为氢、氯或甲氧基，R.sup.5为氢、乙酰基、丙酰基、苯甲酰基、氯苯甲酰基、甲氧基苯甲酰基或苯乙酰基，但要求R.sup.1到R.sup.4中的2个或3个基团为氢。许多对应的苯并[f]喹啉类化合物，可以通过氧化反应制备这些苯并环丙二酮类化合物，适用于控制或预防哺乳动物的脑血供不足，或改善认知功能。它们可以通过各种方法生产，并制备成药物组合物。
• Process for the preparation of benzo (F) quinolinones
  申请人：Eli Lilly and Company

  公开号：US05239075A1

  公开（公告）日：1993-08-24

  This invention relates to a process for the preparation of hexa- and octahydrobenzo[f]quinolin-3-ones.

  本发明涉及一种制备六氢和八氢苯并[f]喹啉-3-酮的方法。
• Benzo[f]quinoline intermediates
  申请人：Hoffmann-La Roche Inc.

  公开号：US04749791A1

  公开（公告）日：1988-06-07

  Benzazecinediones of the formula ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen or chlorine, R.sup.3 is hydrogen, fluorine, chlorine, bromine or methoxy, R.sup.4 is hydrogen, chlorine or methoxy and R.sup.5 is hydrogen, acetyl, propionyl, benzoyl, chlorobenzoyl, methoxybenzoyl or phenylacetyl, with the proviso that 2 or 3 of the groups R.sup.1 to R.sup.4 are hydrogen, as well as many of the corresponding benzo[f]quinolines from which these benzazecinediones can be prepared by oxidation are suitable for the control or prevention of cerebral insufficiency or for the improvement of cognitive functions in mammals. They can be produced according to various processes and can be prepared into pharmaceutical compositions.

  式为##STR1##的苯并氮烯二酮，其中R.sup.1和R.sup.2独立地为氢或氯，R.sup.3为氢、氟、氯、溴或甲氧基，R.sup.4为氢、氯或甲氧基，R.sup.5为氢、乙酰基、丙酰基、苯甲酰基、氯苯甲酰基、甲氧基苯甲酰基或苯乙酰基，但前提是R.sup.1到R.sup.4中的2或3个基团为氢，以及许多相应的苯并[f]喹啉，可以通过氧化制备这些苯并氮烯二酮，适用于控制或预防哺乳动物的脑血供不足或改善认知功能。它们可以根据不同的工艺制备，并可以制备成药物组成物。
• Hexahydrobenzo[f]quinolinones as 5-alpha-reductase inhibitors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0531026A1

  公开（公告）日：1993-03-10

  The invention relates to 1,2,3,4,5,6-hexahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds, and their use as steroid 5α-reductase inhibitors.

  本发明涉及 1,2,3,4,5,6-六氢苯并[f]喹啉-3-酮、含有这些化合物的药物制剂以及它们作为类固醇 5α 还原酶抑制剂的用途。